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The effects of the antihelmintic, ivermectin, were inves-
tigated in recombinantly expressed human a1 homomeric
and a1b heteromeric glycine receptors (GlyRs). At low (0.03
mM) concentrations ivermectin potentiated the response to
sub-saturating glycine concentrations, and at higher (>0.03
mM) concentrations it irreversibly activated both a1 homo-
meric and a1b heteromeric GlyRs. Relative to glycine-gated
currents, ivermectin-gated currents exhibited a dramati-
cally reduced sensitivity to inhibition by strychnine, picro-
toxin, and zinc. The insensitivity to strychnine could not be
explained by ivermectin preventing the access of strych-
nine to its binding site. Furthermore, the elimination of a
known glycine- and strychnine-binding site by site-directed
mutagenesis had little effect on ivermectin sensitivity, dem-
onstrating that the ivermectin- and glycine-binding sites
were not identical. Ivermectin strongly and irreversibly
activated a fast-desensitizing mutant GlyR after it had been
completely desensitized by a saturating concentration of
glycine. Finally, a mutation known to impair dramatically
the glycine signal transduction mechanism had little effect
on the apparent affinity or efficacy of ivermectin. Together,
these findings indicate that ivermectin activates the GlyR
by a novel mechanism.
Ivermectin (22,23-dihydroavermectin B1a) is macrocyclic lac-
tone widely used as an antiparasitic agent in domestic animals
and is considered the drug of choice for lymphatic filariasis and
river blindness (onchocerciasis) in humans (1–3). The target of
its antiparasitic action is believed to be an ivermectin-sensitive
glutamate-gated Cl2 channel receptor (GluClR)1 that exists in
a number of invertebrate phyla (4–7). Ivermectin also acts as
an anticonvulsant in a variety of vertebrate seizure models
(8–10). However, GluClRs have not been demonstrated to exist
in vertebrates, and the anticonvulsant actions of ivermectin in
a mouse seizure model has recently been shown to be mediated
by GABA type A receptors (GABAARs) (10).
The GluClR and the GABAAR belong to the ligand-gated ion
channel superfamily, which also includes the nicotinic acetyl-
choline receptor cation channel (nAchR), the serotonin type 3
receptor cation channel, and the glycine receptor chloride chan-
nel (GlyR) (4, 11–14). The mechanisms of action of ivermectin
and its analogues have been investigated in several members of
this family. For example, ivermectin irreversibly activates the
GluClR over a concentration range from 0.1 to 1 mM, although
at lower concentrations (,0.01 mM) it induces potentiation of
glutamate-gated currents (4, 5). The effects of ivermectin on
the GABAAR also include potentiation of GABA-gated currents
(10, 15, 16) as well as direct, reversible receptor activation (10,
17, 18), although both effects have not always been observed in
some preparations. In addition, ivermectin has been shown to
potentiate acetylcholine-mediated responses in the recombi-
nantly expressed a7 nAChR (19). Finally, ivermectin has long
been known to displace [3H]strychnine in radiolabeled binding
studies (20), implying that it may exert some effect on the
GlyR. Indeed, ivermectin has recently been demonstrated to
act as a use-dependent inhibitor of a GlyR that is endogenously
expressed in primary cultured rat cortical neurons (10).
The effects of ivermectin on a variety of members of the
ligand-gated ion channel superfamily prompted us to test its
actions on recombinantly expressed human a1 homomeric and
a1b heteromeric GlyRs. We find that ivermectin acts as an
allosteric potentiator of glycine-gated currents at low (0.03 mM)
concentrations and as a potent, irreversible agonist at higher
concentrations. In addition, since ivermectin affinity is not
affected by mutations to a well characterized glycine binding
domain, and the pharmacology of ivermectin-gated currents is
different to that of glycine-gated currents, it appears that iver-
mectin acts via a novel mechanism to activate the GlyR.
EXPERIMENTAL PROCEDURES
Mutagenesis and Expression of GlyR cDNAs—The human GlyR a1
and b subunit cDNAs were subcloned into the pCIS2 and pIRES2-
EGFP plasmid vectors (CLONTECH, Palo Alto, CA), respectively. Be-
cause GlyR a subunits can efficiently assemble into functional GlyRs as
either a homomers or a/b heteromers, green fluorescent protein expres-
sion was used as an indicator of GlyR b subunit expression. Site-
directed mutagenesis was performed using the QuickChange mutagen-
esis kit (Stratagene, La Jolla, CA), and the successful incorporation of
mutations was confirmed by sequencing the clones. Adenovirus-trans-
formed human embryonic kidney 293 cells (ATCC CRL 1573) were
passaged in minimum essential medium supplemented with 2 mM
glutamate, 10% fetal calf serum, and the antibiotics penicillin 50 IU/ml
and streptomycin 50 mg/ml (Life Technologies, Inc.). Cells were trans-
fected using a calcium phosphate precipitation protocol (21). When
cotransfecting the GlyR a and b subunits, their respective cDNAs were
combined in a ratio of 1:10 (22). After exposure to transfection solution
for 24 h, cells were washed twice using the culture medium and used for
recording over the following 24–72 h.
Electrophysiology—The cells were observed using a fluorescent mi-
croscope, and currents were measured using the whole cell patch clamp
configuration. Cells were perfused by a control solution that contained
(in mM) 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, with
the pH adjusted to 7.4 with NaOH. Patch pipettes were fabricated from
borosilicate hematocrit tubing (Vitrex, Modulohm, Denmark) and heat-
polished. Pipettes had a tip resistance of 1.5–3 MV when filled with the
standard pipette solution which contained (in mM) 145 CsCl, 2 CaCl2, 2
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MgCl2, 10 HEPES, 10 EGTA, with the pH adjusted to 7.4 with NaOH.
After establishment of the whole cell configuration, cells were voltage-
clamped at 240 mV, and membrane currents were recorded using an
Axopatch 1D amplifier and pCLAMP7 software (Axon Instruments,
Foster City, CA). The cells were perfused by a parallel array of micro-
tubular barrels through with solutions were gravity-induced. The am-
plifier series resistance compensation was used to compensate for at
least 50% of the series resistance error. Experiments were conducted at
room temperature (18–22 °C).
Ivermectin (Sigma) was stored frozen as a 10 mM stock solution in
dimethyl sulfoxide for up to 2 weeks. When dissolved into the perfusion
solution, the final concentration of dimethyl sulfoxide was no more than
0.3%. Strychnine, picrotoxin, and zinc were also prepared from frozen
stocks at concentrations of 10 mM (in water), 100 mM (in dimethyl
sulfoxide), and 100 mM (in water), respectively.
The effects of ivermectin were tested with the following procedure.
First, the glycine dose-response was measured by applying increasing
concentrations of glycine at 30-s intervals. Then two brief applications
of glycine at the half-saturating concentration (EC50) were followed by
two brief applications at a saturating concentration (10 3 EC50), all at
30-s intervals. Provided the current amplitude remained constant, the
averaged current amplitudes were used as the control. Following this,
ivermectin was applied until a steady-state response was attained
(usually ,1 min). Because ivermectin induced irreversible activation,
only a single ivermectin treatment was obtained per cell, and the
coverslip was discarded after each recording.
Data Analysis—Glycine dose responses were measured by applying a
series of glycine concentrations to each cell. Glycine dose-response
parameters were quantitated by fitting the Hill equation to individual
dose responses by a nonlinear curve fitting routine (Origin 4.0, North-
ampton, MA). The EC50 and Hill coefficient (nH) values thus obtained
were then averaged as means 6 S.E. The irreversible nature of iver-
mectin activation meant that only one concentration could be applied on
one cell. In this case, current amplitude was normalized to the saturat-
ing (10 3 EC50) glycine-induced current in the same cell and then
averaged with the data recorded from other cells at the same concen-
tration. The pooled results recorded at different concentrations from
different cells were then fitted with the Hill equation to obtain the
Imax/Imax(Gly), EC50, and Hill coefficient (nH) values. The nH values
obtained in such a manner must be interpreted with caution as curve
fits to averaged dose responses typically underestimate its true value.
Because of this uncertainty, the present study avoids drawing infer-
ences from nH data. Where possible, statistical significance was deter-
mined by one-way ANOVA, with p , 0.05 representing significance.
However, because only a single EC50 value was obtained for the pooled
ivermectin dose responses, a simple one-way ANOVA could not always
be performed. In such cases the statistical significance of differences in
ivermectin responses between wild-type and mutant GlyRs was deter-
mined with a general linear model of two-way analysis of variance
(ANOVA) (Minitab 13.20, State College, PA), with the two factors being
ivermectin concentration and phenotype, with p , 0.01 representing
significance. The p values thus obtained using this analysis are shown
in Table II.
RESULTS
Ivermectin Activation of the GlyR—Examples of the effects of
ivermectin on wild-type (WT) a1 homomeric GlyRs are shown
in Fig. 1. It can be seen that ivermectin, at concentrations of 0.3
mM or greater, induced irreversible channel activation. Such
effects were not reversed by a 10-min wash in ivermectin-free
control solution. Because of its irreversible effect, only one
ivermectin application could be recorded from each cell. Hence,
the traces in Fig. 1 corresponding to different ivermectin con-
centrations were recorded from different cells, although both
traces in any given row were recorded from the same cell. It is
notable that the ivermectin-induced activation was much
slower than that induced by glycine, particularly at the lower
ivermectin concentrations. Although a 0.03 mM application of
ivermectin activated little current, it did result in a strong
FIG. 1. Ivermectin potentiation and activation of the GlyR. In this and all subsequent figures, all displayed traces were recorded from cells
expressing WT or mutated a1 homomeric GlyRs using whole cell recording. In this figure, traces in different rows were obtained from different cells,
although both traces on a single row were from the same cell. Each cell was treated first with two applications of a half-saturating (25 mM) glycine
concentration, followed by two applications of a saturating (250 mM) glycine concentrations (left panels). Following this, ivermectin was applied at
the indicated concentration, and glycine responses were recorded again (right panels).
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potentiation of the current activated by a sub-saturating gly-
cine concentration (Fig. 1, top panel). This effect is considered
further below. Ivermectin was a partial agonist of the GlyR,
with a saturating (30 mM) concentration activating 77 6 6%
(n 5 6) of the current activated by a saturating (250 mM)
concentration of glycine. When ivermectin was applied at a
saturating concentration, glycine activated no additional cur-
rent (Fig. 1, bottom panel), indicating that ivermectin and
glycine compete for the activation of the same population of
GlyRs.
The ivermectin dose-response relationship was constructed
by normalizing the magnitude of the current activated by a
known concentration of ivermectin to the magnitude of the
current activated by a saturating concentration (10 3 EC50) of
glycine in the same cell. Thus, a single point on a dose-response
curve was obtained from each cell. By measuring the relative
magnitudes of ivermectin-gated currents at a single concentra-
tion in many cells, a pooled ivermectin dose response was
compiled as shown in Fig. 2A. Each point in this figure was
averaged from at least three different cells. The curve, which
was fit to all points, had an EC50 of 0.39 mM and an nH of 0.59.
The ivermectin EC50 and nH values for all other GlyR con-
structs investigated in this study were calculated in the same
way, and all results are summarized in Table I. The respective
glycine EC50 and nH values for the same GlyR constructs were
calculated from entire dose responses measured in individual
cells, and these results are also summarized in Table I.
GlyRs in vivo are considered to exist as heteromers compris-
ing a and b subunits in the ratio 3:2 (23). Since the a1/b
heteromeric GlyR differs pharmacologically from the a1 homo-
meric GlyR (22, 24), it was possible that the heteromers may
respond differently to ivermectin. However, the presence of the
b subunit had no significant effect on ivermectin sensitivity
(Table I). Hence, all experiments described in the remainder of
this paper were performed on a1 homomeric GlyRs.
We then investigated the ivermectin current-voltage (I-V)
relationship of the WT GlyR according to the following proce-
dure. First, a saturating concentration (0.25 mM) of glycine was
applied at 240 mV, followed by a repeated glycine application
and a 3 mM (saturating) ivermectin application at a specific
holding potential of 270, 240, 220, 0, 20, or 40 mV. The
glycine- and ivermectin-induced currents measured at the spe-
cific holding potential were normalized to the initial glycine
current recorded at 240 mV to generate the I-V curve dis-
played in Fig. 2B. This figure demonstrates that, in contrast to
the linear I-V relationship that characterized glycine-gated
currents, the ivermectin-gated currents displayed weak out-
ward rectification. Differences in rectification between iver-
mectin- and glutamate-gated conductances have also been ob-
served in the GluClR (4). The reversal potentials for currents
activated by both glycine (20.2 mV) and ivermectin (13.7 mV)
approximated to the equilibrium potential (0 mV) for chloride
ions.
Ivermectin Potentiation of Glycine-gated Currents—As
shown in Fig. 1 (top panel), low concentrations (0.03 mM) of
ivermectin potentiated glycine-gated currents. Both the glycine
and ivermectin dependence of this effect were investigated. As
shown in the example in Fig. 3A, 0.03 mM ivermectin dramat-
ically increased the magnitude of current activated by a 10 mM
(EC5) concentration of glycine (upper panel) but appeared to
slightly diminish the amplitude of currents activated by a 250
mM (saturating) glycine concentration (lower panel). The mag-
nitude of the potentiation induced by 0.03 mM ivermectin was
measured at the following glycine concentrations (with approx-
imate EC values in parentheses): 10 (EC5), 25 (EC50), 30
(EC60), 100 (EC95), and 250 mM (EC100). The mean percentage
change in glycine-gated current at each concentration is sum-
marized in Fig. 3B. Since ivermectin had no significant effect at
the EC60 glycine concentration, it is not possible to conclude
that it acted by a simple enhancement of the apparent glycine
affinity. The results suggest instead that ivermectin selectively
potentiated currents activated by the lowest glycine concentra-
tions, without dramatically changing the glycine EC50 value.
The significant reduction in current magnitude at 250 mM gly-
cine is expected since ivermectin is a partial agonist.
The range of ivermectin concentrations that induced poten-
tiation of glycine currents was very narrow. In fact, 0.01 mM
ivermectin induced no significant potentiation of glycine re-
sponses nor did it induce significant direct current activation
(n 5 4 cells). On the other hand, 0.1 mM ivermectin directly
activated 27 6 5% (n 5 4 cells) of the saturating glycine-gated
current but also induced no significant potentiation of glycine-
gated currents (n 5 4 cells). At a concentration of 0.03 mM,
ivermectin exhibited a dual effect as a potentiator and an
activator inducing 7.8 6 1.5% (n 5 4 cells) of the saturating
glycine-gated current.
Pharmacology of Ivermectin-gated Currents—The pharmaco-
logical profile of ivermectin-gated currents was investigated by
measuring the inhibitory potencies of strychnine, picrotoxin,
and zinc. Strychnine is considered to act as a classical compet-
itive antagonist of glycine with an affinity in the nanomolar
FIG. 2. Properties of ivermectin-gated currents. A, the ivermec-
tin dose-response curve was compiled as described in the text. The curve
was fitted with an EC50 of 0.39 mM and an nH of 0.59. B, current-voltage
relationship curves for glycine- and ivermectin-gated currents were
determined as described in the text. Current amplitude was normalized
to the saturating concentration (250 mM) glycine-induced current re-
corded at 240 mV. The reversal potential was 20.2 mV for glycine and
3.7 mV for ivermectin.
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range (25–27). As shown in Fig. 4A (left panel), 10 mM strych-
nine strongly inhibited the current activated by a saturating
(250 mM) concentration of glycine. However, 10 mM strychnine
had no significant inhibitory effect on the current activated by
a saturating (3 mM) concentration of ivermectin. The effect of
strychnine was also investigated at the lower ivermectin con-
centration of 0.3 mM, where it was found to induce significant
inhibition. The effect of 10 mM strychnine on glycine- and iver-
mectin-gated currents are summarized in Table II. The results
indicate that ivermectin-gated currents have a dramatically
reduced sensitivity to strychnine.
Since ivermectin is an irreversible agonist, the reduction in
strychnine efficacy could have resulted from the bound iver-
mectin sterically hindering strychnine from accessing its bind-
ing site. To investigate this possibility, we applied strychnine
first and sought to determine whether pre-bound strychnine
could inhibit the subsequent rate of activation of ivermectin-
induced currents. The time constant of strychnine unbinding
was estimated as indicated in Fig. 4B, left panel. Following
removal of strychnine, the saturating current magnitude was
regularly monitored by brief applications of 250 mM glycine.
Fitting first-order exponential curves to the current peaks en-
abled us to estimate a mean unbinding time constant for 10 mM
strychnine of 5.2 6 0.26 s (n 5 5) and for 100 mM strychnine of
22.1 6 1.4 s (n 5 5). The mean time constant of current
activation by 3 mM ivermectin was 4.4 6 1.0 s (n 5 6). This
value was not significantly different to the unbinding time
constant of 10 mM strychnine (one-way ANOVA, p . 0.05) but
was significantly faster than the unbinding time constant of
100 mM strychnine (p , 0.05). Therefore, if strychnine and
ivermectin are competing for a common or overlapping binding
site, the dissociation rate of 100 mM strychnine should be the
rate-limiting step in the activation of ivermectin-gated cur-
rents. An example of an experiment designed to investigate
this possibility is shown in Fig. 4B, right panel. When 3 mM
ivermectin was applied immediately after a long (30 s) appli-
cation of 100 mM strychnine, the mean current activation time
constant was 2.9 6 0.72 s (n 5 3). This value was not signifi
TABLE I
Summary of glycine and ivermectin effects on WT and mutant GlyRs
All mutations were incorporated into a homomeric GlyRs.
GlyR
Glycine Ivermectin
EC50 (-fold change) nH n
EC50 (-fold
change) nH Imax/Imax(Gly) p n
a
mM mM
WT/a 0.026 6 0.009 (1) 3.4 6 0.31 4 0.39 (1) 0.59 0.77 6 0.06b 42.6
WT/ab 0.024 6 0.005 (0.92) 3.0 6 0.73 4 0.29 (0.74) 0.95 0.68 6 0.04b 0.71 31.3
F159Y 0.012 6 0.002 (0.46) 2.5 6 0.24 4 0.56 (1.4) 1.26 0.83 6 0.06b 0.44 18.3
Y161F 0.016 6 0.006 (0.62) 1.7 6 0.43 4 2.7 (6.9) 1.6 0.71 6 0.08b 0.001 18.3
Y202F 5.5 6 2.4 (212) 1.3 6 0.17 6 1.9 (4.9) 0.79 0.81 6 0.09b 0.003 27.3
T204A 6.4 6 2.9 (246) 2.5 6 0.80 4 2.6 (6.7) 3.6 0.83 6 0.09b 0.09 18.3
I244A 0.78 6 0.23 (30) 1.5 6 0.26 4 0.32 (0.82) 0.82 1.7 6 0.2b ,0.001 18.3
R271Q 7.1 6 0.19 (273) 1.7 6 0.20 5 7.9 (20) 3.2 4.7 6 1.2b 0.009 17.4
a The first n value indicates the number of cells used to calculate the EC50 and the second indicates the number used to calculate Imax/Imax(Gly).
b Significant differences between ivermectin- and glycine-gated currents using one-way ANOVA (p , 0.05) are shown. The p values for
ivermectin were determined as outlined under “Experimental Procedures.”
FIG. 3. Ivermectin potentiation of submaximal glycine-gated currents. A, pre-applied 0.03 mM ivermectin potentiated the currents
activated by a 10 mM (EC5) glycine concentration (upper trace) and slightly reduced the currents activated by a 250 mM (saturating) glycine-induced
current (lower trace). Both traces were from different cells. B, glycine concentration dependence of potentiation by 0.03 mM ivermectin. All values
were averaged from at least three cells.
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cantly different to the activation time constant in the absence
of strychnine (one-way ANOVA, p . 0.05), indicating that
pre-bound strychnine has no effect on the activation rate of
ivermectin-gated currents. Therefore, in contrast to its effect on
glycine-gated currents, strychnine is a relatively weak antag-
onist of ivermectin-gated currents.
Although the mechanism of action of picrotoxin on the GlyR
has not been unequivocally resolved, evidence to date indicates
that it acts as an allosteric inhibitor (23, 28). As shown in Fig.
4C (left panel), 1 mM picrotoxin strongly inhibited currents
activated by 250 mM glycine. However, in the same cell it was
apparent that the same picrotoxin concentration had little ef-
fect on currents activated by 3 mM ivermectin (Fig. 4C, right
panel). The inhibitory effects of picrotoxin on both glycine- and
ivermectin-gated currents are summarized in Table II. The
results indicate that picrotoxin is a comparatively poor antag-
onist of ivermectin-activated currents.
Zinc acts as an allosteric potentiator of glycine-gated cur-
rents at low (,3 mM) concentrations and as a competitive an-
tagonist at higher concentrations (29, 30). As shown in Fig. 4D,
1 mM zinc strongly inhibited glycine-gated currents but had
little effect on ivermectin-gated currents. The averaged results
displayed in Table II confirm that zinc antagonism of ivermec-
tin-gated currents is also very weak. Taken together, these
results indicate that ivermectin-gated currents are pharmaco-
logically distinct from glycine-gated currents.
Effects of Glycine-binding Site Mutations on Ivermectin-
gated Currents—Previous studies have revealed that two re-
gions in the GlyR a1 subunit external N-terminal domain,
Phe159–Gly160–Tyr161 and Lys200–Tyr202–Thr204, are major de-
terminants of the glycine- and strychnine-binding sites (26, 27,
31–33). Accordingly, the effects of ivermectin were investigated
on the F159Y, Y161F, Y202F, and T202A mutant GlyRs. Since
ivermectin remained an irreversible agonist of all these mutant
GlyRs, the ivermectin dose responses were measured as de-
scribed in Fig. 2A. The glycine dose responses for each mutant
FIG. 4. Pharmacology of ivermec-
tin-gated currents. A, a 10 mM concen-
tration of strychnine strongly inhibits
currents activated by a saturating (250
mM) concentration of glycine (left panel)
but has little effect on the current acti-
vated by a saturating (3 mM) concentra-
tion of ivermectin (right panel). B, the
time course of recovery from an applica-
tion of 100 mM strychnine is slow and can
be quantitated by regularly monitoring
current with short applications of 250 mM
glycine (left panel). However, a pre-appli-
cation of 100 mM strychnine has little ap-
parent effect on the rate of activation of
ivermectin-mediated currents in the same
cell (right panel). C, a 1 mM concentration
of picrotoxin strongly inhibits currents ac-
tivated by a saturating (250 mM) concen-
tration of glycine (left panel) but has little
effect on the current activated by a satu-
rating (3 mM) concentration of ivermectin
(right panel). D, similarly, 1 mM zinc
strongly inhibits currents activated by a
saturating (250 mM) concentration of gly-
cine (left panel) but has little effect on the
current activated by a saturating (3 mM)
concentration of ivermectin (right panel).
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GlyR were also measured, and all results are summarized in
Table I. Consistent with previous studies (26, 27, 31–33), the
glycine sensitivity was dramatically reduced (.200-fold) by the
Y202F and T204A mutations, although the sensitivity was
modestly increased by the F159Y and Y161F mutations. How-
ever, the ivermectin sensitivity was only weakly affected (1.4–
6.9-fold) by any of these mutations (Table I). In addition, 0.03
mM ivermectin also potentiated half-saturating concentration
glycine-induced current in each of the 4 mutant GlyRs (not
shown). Thus, ivermectin does not act by binding to the glycine-
binding site formed by Tyr202 and Thr204.
Effect of a Startle Disease Mutation on Ivermectin Efficacy—
R271Q is a heritable mutation in the human GlyR a1 subunit
that underlies familial startle disease (34). This mutation has
previously been shown to induce a large reduction in both
glycine sensitivity and single channel conductance (35, 36). In
addition, this mutation also converts the glycinergic agonists,
b-alanine and taurine, from agonists into competitive glycine
antagonists (37, 38). The effects of this mutation are most
likely to be mediated by a disruption in the signal transduction
process linking the ligand-binding sites to the channel activa-
tion gate (38, 39). Given these findings, we hypothesized that
the R271Q mutation may also affect the efficacy with which
ivermectin is able to activate the channel. Although 0.03 mM
ivermectin induced little direct activation of the R271Q mutant
GlyR, it potentiated the magnitude of currents activated by a 7
mM (EC50) concentration of glycine (Fig. 5A). Since this is
similar to the effect of ivermectin on the WT GlyR, the muta-
tion has apparently not altered the receptor sensitivity to low
ivermectin concentrations. On the other hand, although the
WT GlyR is strongly activated by 3 mM ivermectin, this concen-
tration induced only a weak direct activation of the R271Q
mutant GlyR (Fig. 5B). In addition, we were surprised to find
that prior exposure of GlyRs to 3 mM ivermectin converted
glycine into an irreversible agonist (Fig. 5B), an effect that is
considered further below. When applied at a concentration of
30 mM, the ivermectin-gated current was 4.8 6 1.2 (n 5 4) times
the magnitude of the current activated by a saturating (70 mM)
glycine concentration (e.g. Fig. 5C). Once currents were maxi-
mally activated by ivermectin, a subsequent application of 7
mM glycine induced an additional small irreversible current
(Fig. 5C). The mean glycine and ivermectin EC50 and nH values
for the R271Q mutant GlyR are given in Table I. The results
indicate that although this mutation decreased the glycine
sensitivity by a factor of 273, the ivermectin sensitivity was
decreased only by a factor of 20. Taken together, these obser-
vations suggest that R271Q disrupted the glycine gating mech-
anism to a much greater extent than that of ivermectin. By
comparison, it is relevant to note that the binding site muta-
tions, Y202F and T202A, had no significant effect on the rela-
tive magnitude of ivermectin- versus glycine-gated currents
(Table I), although their glycine sensitivity was similar to that
of R271Q.
As indicated above, prior application of 3 mM ivermectin
induced glycine to irreversibly increase the current magnitude.
It is noteworthy that this irreversible “glycine-enhanced” cur-
rent was much larger in magnitude than that induced by a
saturating glycine concentration prior to ivermectin exposure
(Fig. 5B). In fact, the magnitude of current activated by 7 mM
(EC50) glycine was increased by 5.8 6 2.1 (n 5 4) times after
exposure to 3 mM ivermectin. The pharmacology of this glycine-
enhanced current was investigated by testing the effect of
picrotoxin. In the WT GlyR, picrotoxin acts as a competitive
antagonist of glycine-gated currents (28). However, in the
R271Q mutant GlyR, picrotoxin is converted into a noncompet-
itive inhibitor of glycine-gated currents with an IC50 of 5 mM
(28). When applied at a concentration of 1 mM, picrotoxin in-
hibited the irreversible glycine-enhanced current by 15 6 7%
(n 5 4), indicating that this current is dramatically less picro-
toxin-sensitive than the glycine-gated current. Given the weak
picrotoxin sensitivity and the irreversible activation, this cur-
rent more closely resembles the ivermectin-gated current than
the glycine-gated current. The glycine exposure reduced the
mean ivermectin EC50 value from 7.9 to 6.6 mM. These obser-
vations support the conclusion that a short application of gly-
cine significantly increases the efficacy with which the pre-
bound ivermectin can irreversibly activate the channels.
Effect of a Fast Desensitization Mutant on Ivermectin-gated
FIG. 5. Effects of ivermectin on the R271Q mutant GlyR. A–C,
each cell was treated first with two applications of a half-saturating (7
mM) glycine concentration, followed by two applications of a saturating
(70 mM) glycine concentration (left panels). Following this, ivermectin
was applied at the indicated concentration, and glycine responses were
recorded again (right panels). Note the potent irreversible activation by
7 mM glycine in B (right panel).
TABLE II
Percentage inhibition by picrotoxin, strychnine, and zinc of glycine- and ivermectin-induced currents in the WT GlyR
Agonist 10 mM strychnine 1 mM picrotoxin 0.3 mM picrotoxin 1 mM Zn21
0.25 mM glycine 90 6 4.7% (3) 96 6 2.2% (3) 84 6 5.1% (3)
0.3 mM ivermectin 40 6 4% (4)a 34 6 6% (5)a 9.3 6 2.4% (3)a 14 6 7.8% (3)a
3 mM ivermectin 0% (3)a 13 6 8% (3)a 0% (3)a
a Significant differences with respect to WT GlyR values using one-way ANOVA (p , 0.05) are shown, and n values are given in parentheses.
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Responses—A final series of experiments was directed at de-
termining whether a prolonged glycine exposure could induce
cross-desensitization of ivermectin-gated currents. This exper-
iment is difficult to perform using recombinantly expressed WT
GlyR a1 subunits because these display a slow rate of desensi-
tization. Indeed, most of the observed decay of glycine-gated
currents in whole cell recordings is due to chloride shift effects
(38). However, since glycine-gated currents in the I244A mu-
tant GlyR desensitize rapidly with a time constant of about 1 s
(39), this mutant receptor provides a suitable model for inves-
tigating the effects of glycine-induced desensitization on iver-
mectin-gated currents.
In the WT GlyR, a saturating concentration (30 mM) of iver-
mectin induced a current that decayed at approximately the
same rate as the glycine-gated current recorded in the same
cell (Fig. 6A). Furthermore, when ivermectin was coapplied
with glycine, the rate of current decay was not changed (Fig.
6B). Similar results were observed in four cells. As discussed
below, these results contrast dramatically with those recorded
from the I244A mutant GlyR.
Apart from its effects on desensitization, I244A also reduced
both the glycine sensitivity and the agonist efficacy of b-alanine
and taurine relative to glycine (39). The glycine and ivermectin
EC50 and nH values for the I244A mutant GlyR are displayed in
Table I. The I244A mutation reduces the glycine sensitivity by
a factor of 30, although the ivermectin sensitivity is not af-
fected. The recovery time constant from the glycine-induced
fully desensitized state to the resting closed state was meas-
ured to be 3.2 6 0.49 s (n 5 3). An example of a glycine-gated
current recorded from a cell expressing the I244A mutant GlyR
is displayed in Fig. 6C. The rapid rate of desensitization of this
current is apparent. An example of an ivermectin-gated current
recorded from the same cell 30 s later is also shown (Fig. 6C).
It is apparent that ivermectin not only irreversibly activates
this mutant GlyR but that the magnitude of the current acti-
vated by a saturating (30 mM) concentration of ivermectin is
greater than that activated by a saturating (8 mM) concentra-
tion of glycine. Indeed, the ratio of the saturating ivermectin-
versus glycine-gated current averaged from four cells was 1.7 6
0.2 (n 5 4), suggesting that the I244A mutation reduces glycine
efficacy. This observation is consistent with a previous study
that concluded that the mutation disrupted the glycine signal
transduction mechanism (39).
As displayed in Fig. 6D, ivermectin potently activated the
I244A mutant GlyR after the receptor was completely desensi-
tized to glycine. The mean ratio of the saturating ivermectin-
versus glycine-gated current after glycine-induced desensitiza-
tion was 1.3 6 0.2 (n 5 4), which using a one-way ANOVA was
not significantly different from that obtained before glycine-
induced desensitization (p . 0.05). The rate of ivermectin-
induced channel activation was not affected by the presence of
glycine. The mean activation time constant of currents gated by
30 mM ivermectin in the presence of glycine was 5.3 6 2.0 s (n 5
4), whereas in the absence of glycine was 3.6 6 0.6 s (n 5 3). By
FIG. 6. Comparison of the effects of ivermectin on the WT and I244A mutant GlyRs. Traces in both A and B were recorded from WT
GlyRs, whereas traces in C and D were recorded from I244A GlyRs. A, examples of WT GlyR currents activated by the indicated (saturating)
concentrations of glycine and ivermectin in the same cell. B, ivermectin (30 mM) has little additional effect when applied to WT GlyRs already
maximally activated by 250 mM glycine. C, examples of I244A mutant GlyR currents activated by the indicated (saturating) concentrations of
glycine and ivermectin. Both traces were recorded from the same cell. Note the larger amplitude and the slower decay rate of the ivermectin-gated
current. D, a saturating concentration of ivermectin is still able to irreversibly activate a large current even after complete desensitization of the
I244A mutant GlyR to a saturating glycine concentration.
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using a one-way ANOVA, these values are not significantly
different (p . 0.05). These results demonstrate that ivermectin
activates the I244A mutant GlyR after it has been completely
desensitized to a prior glycine application. Furthermore, the
ivermectin activation rate is not changed in the glycine-in-
duced desensitized state.
DISCUSSION
Novel Mechanism of Ivermectin Activation—Ivermectin ex-
erted dual effects on the WT GlyR. At low (0.03 mM) concentra-
tions it potentiated the response to sub-saturating glycine con-
centrations, and at higher ($0.03 mM) concentrations it directly
activated GlyR Cl2 currents. These effects are similar to those
of ivermectin on the Caenorhabditis elegans ab heteromeric
GluClR and the Drosophila homomeric a GluClR (Table III).
This functional similarity may reflect the close phylogenetic
relationship between the GluClR and GlyR gene families (14).
However, the results of the present study contrast with those
recently found in GlyRs from cultured cortical neurons, where
1 mM ivermectin inhibited glycine-activated currents in a use-
dependent manner, while simultaneously slowing the channel
closing rate (10). Differences in ivermectin effects may depend
on subunit composition (Table III), and since the subunit com-
position of the GlyR studied in (10) is undefined, it is not
possible at present to resolve these differences.
Ivermectin also exerts a range of effects on some other mem-
bers of the ligand-gated ion channel superfamily. For example,
it reversibly activates recombinantly expressed a1b2, a1b1g2,
a1b2g2, a1b2g2s, a1b3g2, and a1g2s GABAARs (10, 18) as well as
a GABA-mediated Cl2 current in dorsal root ganglion neurons
(17). Low ivermectin concentrations (,0.1 mM) potentiate
GABA-mediated Cl2 currents in hippocampal neurons (15),
GABAARs expressed from chick brain mRNA (16), as well as
recombinantly expressed a1b1g2, a1b2g2, and a1b3g2 GABAARs
(10). Finally, in recombinantly expressed a7 homomeric
nAchRs, 30 mM ivermectin enhances the acetylcholine-evoked
current but displays no agonist activity (19). The recently re-
ported potentiating effect of ivermectin on P2X4 receptor chan-
nels (40) indicates that the effects of ivermectin are not limited
to members of the ligand-gated ion channel superfamily.
The present study demonstrates that ivermectin-gated cur-
rents are relatively insensitive to picrotoxin (Table II). This
contrasts with the effects of picrotoxin on the GluClR, where
the picrotoxin sensitivity was similar for ivermectin- and glu-
tamate-gated currents (Table III). The present study also found
that the ivermectin-gated currents exhibited a dramatically
reduced sensitivity to strychnine and zinc (Table II). The re-
duction in strychnine potency could not be explained by iver-
mectin preventing the access of strychnine to its binding site.
The novel pharmacology of the ivermectin-induced activated
state supports the conclusion that ivermectin activates the
GlyR by a novel mechanism. In the a7 nAChR, ivermectin
potentiation also resulted in a modification of the receptor
pharmacological profile (19).
In addition to activating the channels by a novel mechanism,
it is likely that ivermectin binds to a novel, as yet unidentified,
binding site. This study has shown that the mutation of known
glycine-binding sites had very little effect on ivermectin sensi-
tivity (Table I). In particular, the Y202F and T204A mutations,
which strongly disrupted the apparent glycine affinity, had
little effect on ivermectin sensitivity. Thus, although the iver-
mectin- and glycine-binding sites may overlap to some degree,
the two molecules clearly do not bind to an identical set of
contact sites. Since Tyr202 is both a glycine- and strychnine-
binding site (26, 27), the observation that ivermectin does not
bind to Tyr202 may explain the reduced strychnine sensitivity
of the ivermectin-gated response.
Further evidence for a novel mechanism of action by iver-
mectin was sought by investigating whether it could activate a
GlyR that had already been completely desensitized to glycine.
As displayed in Fig. 6D, ivermectin strongly and irreversibly
activated the I244A mutant GlyR after it had previously been
completely desensitized to glycine, suggesting that it could
return desensitized channels directly to the activated state.
This strongly supports the previous conclusion that ivermectin
activates the GlyR via a novel mechanism.
Allosteric Disruption of the Ivermectin Activation Mecha-
nism—The mechanism of action of ivermectin was investigated
further by examining the effect of the R271Q mutation. This
mutation, which is a cause of human startle disease, has been
shown to reduce the apparent affinities of the agonists glycine,
b-alanine, and taurine (37, 38). It also converts taurine and
b-alanine into competitive antagonists of glycine, without dra-
matically affecting their binding affinities (38). These effects
are consistent with a model whereby R271Q completely dis-
rupts the signal transduction pathway linking the taurine and
b-alanine agonist-binding sites to the activation gate (39). Al-
though the mutation appears to have a proportionately greater
disruptive effect on the agonist efficacy of the relatively lower
TABLE III
Comparison of glutamate- and ivermectin-PO4-gated currents in various GluClRs
Receptor
Glutamate Ivermectin-PO4 Ivermectin
potentiation of
glutamate-gated
currents
Ref.
Agonist activity Picrotoxinsensitivity Agonist activity
Picrotoxin
sensitivity
C. elegans None NAa Irreversible Low NA 4, 41
GluCla
homomer
EC50 5 0.14 mM IC50 5 59 mM
C. elegans Reversible High None NA None 4, 41
GluClb
homomer
EC50 5 380 mM IC50 5 0.1 mM
C. elegans Reversible Low Irreversible Low Strong (500%) 4, 41
GluClab
heteromer
EC50 5 1360 mM IC50 5 42 mM EC50 5 0.19 mM IC50 5 52 mM
C. elegans Weak, reversible Very low Irreversible Very low ? 6
GluCla2 EC50 5 208mM IC50 .100 mM EC50 5 0.11 mM IC50 .100 mM
homomer2
C. elegans Reversible Very low Irreversible Very low ? 6
GluCla2b
heteromer
EC50 5 62 mM IC50 .100 mM EC50 5 0.10 mM IC50 .100 mM
Drosophila Reversible Very low Irreversible Very low Weak (24%) 5
GluCl a
homomer
EC50 5 23 mM IC50 . 500 mM EC50 5 0.04 mM IC50 . 500 mM
a NA, not applicable.
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affinity agonists, b-alanine and taurine, it also reduces the
agonist efficacy of glycine (38, 39). This observation also sug-
gests that since ivermectin activates the GlyR with a higher
affinity than does glycine, the R271Q mutation should have a
proportionately weaker disruptive effect on the ivermectin ag-
onist transduction mechanism. Indeed, by demonstrating that
the ivermectin sensitivity is little affected by R271Q and that
the maximum ivermectin-gated current is about 5 times that
activated by a saturating glycine concentration, this study
demonstrates that the glycine agonist transduction mechanism
is disrupted to a greater extent than that of ivermectin.
The I244A mutation causes relatively small reductions in the
apparent agonist affinities of glycine, b-alanine, and taurine
and results in b-alanine and taurine being converted into par-
tial agonists relative to glycine (39). Thus, this mutation in-
duces a similar, but relatively weaker, phenotype than that
induced by R271Q. Hence, it is not surprising that the I244A
mutation has little effect on ivermectin sensitivity (Table I).
Furthermore, since the mutation disrupted the glycine signal
transduction pathway to a relatively small extent (39), it may
be expected that the ratio of the peak ivermectin-gated current
to peak glycine-gated current would not be as large as it is for
R271Q. Indeed, the mean ratio for the I244A mutant GlyR was
1.7, whereas the corresponding ratio for the R271Q mutant
GlyR was 4.8 (Table I). Hence, the results are consistent with
the idea that I244A also disrupts the ivermectin agonist trans-
duction mechanism to a lesser extent than the glycine trans-
duction mechanism.
Conclusion—This study concludes that ivermectin-gated
currents in the GlyR are similar to those in some GluClRs in
that they potentiate agonist responses at low concentrations
and irreversibly activate the receptor at higher concentrations.
However, the GlyR differs in that the ivermectin-gated cur-
rents have a different pharmacology to glycine-gated currents.
Consistent with this observation, this study demonstrates that
the ivermectin- and glycine-binding sites are not identical. In
addition, the observation that ivermectin potently activates a
mutant GlyR after its response to glycine is completely desen-
sitized provides strong evidence for a novel mechanism of ac-
tivation. Furthermore, mutations that are known to disrupt the
agonist signal transduction mechanism have a relatively small
effect on the ivermectin agonist transduction mechanism rela-
tive to those of glycine, b-alanine, or taurine. Together, these
findings indicate that ivermectin activates the GlyR by a novel
mechanism.
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